RIBOXX

riboxx-logo

The business of Riboxx consists of two distinct product lines: LIFE SCIENCES and PHARMA. Riboxx LIFE SCIENCES develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference: small interfering RNA (siRNA) and microRNA (miRNA). RNA interference is a new technology broadly used in life science. With the help of RNA interference, genotype-phenotype correlation studies as well as identification of gene expression patterns are possible. The ... core expertise of Riboxx LIFE SCIENCES is RNA synthesis and analytics. The direct applications of this technology are in the field of RNA interference, more precisely in vivo. Here, Riboxx has developed innovative molecular tools for gene silencing in vivo such as the IVORI® siRNA, the CONTRAmir® and CONmir®. The Riboxx RNAi-technology is robust, easy-to-use and reliable. Riboxx PHARMA has developed two families of TLR & RLR agonists with indications in the fields of oncology, virus infections and autoimmune disorders. The development pipeline at Riboxx comprises: - RIBOXXIM® compounds, for treatment of cancer or virus infections - RIBOXXON® compounds, for treatment of cancer and autoimmune diseases RIBOXXIM® and RIBOXXON® include more than 20 proprietary Active Pharmaceutical Ingredients (API) that possess unique properties as to potency, analytical purity, bioavailability, and safety.

#SimilarOrganizations #People #Financial #Website #More

RIBOXX

Social Links:

Industry:
Biotechnology Genetics

Founded:
2009-05-07

Address:
Radebeul, Sachsen, Germany

Country:
Germany

Website Url:
http://www.riboxx.com

Total Employee:
11+

Status:
Active

Contact:
(490) 351-8336

Total Funding:
1.18 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Google Universal Analytics Apache Mobile Non Scaleable Content Euro Visa Magento


Similar Organizations

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

Current Employees Featured

not_available_image

Hing Chan
Hing Chan CEO & Founder @ Riboxx
CEO & Founder

jacques-rohayem_image

Jacques Rohayem
Jacques Rohayem CEO & Founder @ Riboxx
CEO & Founder

Founder


not_available_image

Hing Chan

jacques-rohayem_image

Jacques Rohayem

Investors List

technologiegrnderfonds-sachsen_image

TGFS - Technologiegründerfonds Sachsen

TGFS - Technologiegründerfonds Sachsen investment in Series A - Riboxx

technologiegrnderfonds-sachsen_image

TGFS - Technologiegründerfonds Sachsen

TGFS - Technologiegründerfonds Sachsen investment in Series A - Riboxx

technologiegrnderfonds-sachsen_image

TGFS - Technologiegründerfonds Sachsen

TGFS - Technologiegründerfonds Sachsen investment in Seed Round - Riboxx

Official Site Inspections

http://www.riboxx.com

  • Host name: r14169.agenturserver.it
  • IP address: 156.67.232.87
  • Location: Germany
  • Latitude: 51.2993
  • Longitude: 9.491
  • Timezone: Europe/Berlin

Loading ...

More informations about "Riboxx"

riboxx RNA Technologies - home

Phone+49 (0)351 8336010 Fax +49 (0)351 83360139 Email order@riboxx.com Technical support Phone +49 (0)351 8336010 Fax +49 (0)351 83360139 Email support@riboxx.comSee details»

riboxx RNA Technologies - home

Contact Order. Phone +49 (0)351 85477880 Email order@riboxx.com. Technical support. Phone +49 (0)351 85477880 Email support@riboxx.comSee details»

riboxx RNA Technologies - About Riboxx

Riboxx life sciences has developed innovative molecular tools for gene silencing in vivo such as the IVORI ® siRNA, the CONTRAmir ® and CONmir ®. riboxx´s technologies are robust, easy …See details»

riboxx RNA Technologies - Management

Before founding riboxx, Rohayem was a group leader and senior researcher at Dresden University of Technology (Germany). He has developed and patented the new technologies …See details»

home - RIBOXX Pharmaceuticals

See details»

Riboxx - Crunchbase Company Profile & Funding

Riboxx PHARMA has developed two families of TLR & RLR agonists with indications in the fields of oncology, virus infections and autoimmune disorders. The development pipeline at Riboxx …See details»

Riboxx GmbH (Riboxx Pharmaceuticals) - Life-Sciences-Europe.com

May 1, 2009 · RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in cancer …See details»

riboxx RNA Technologies - home

Home; products. siRNA. iBONi siRNA; iBONi siRNA controls; modified siRNA. riboLINK siRNA; riboLINK siRNA Controls; IN VIVO siRNA. iVORi siRNA; miRNA mimics. CONmiR ...See details»

Riboxx Company Profile 2024: Valuation, Funding & Investors

Operator of a pharmaceutical company intended to offer a platform for the production of RNA.See details»

Riboxx Company Profile - Office Locations, Competitors, Revenue …

Riboxx is a company that develops ribonucleic acid (RNA) molecules. It offers reagents, prophylactic vaccines, immunomodulators, and other products for cancer treatment and …See details»

Riboxx - Products, Competitors, Financials, Employees, …

Riboxx is a company focused on the development of RNA molecules with unique properties, operating in the biotechnology sector. Use the CB Insights Platform to explore Riboxx's full …See details»

Riboxx - VentureRadar

Riboxx GmbH is an international provider of innovative, customized and tailor-made molecular tools for gene silencing in vitro and in vivo through... ... Find out more about Riboxx, …See details»

PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim

May 18, 2021 · Encapsulation of Riboxxim together with antigens potently activates murine and human dendritic cells, and elevated tumor-specific CD8 + T cell responses are superior to …See details»

Successful Industrial GMP Manufacturing of ... - World Pharma Today

RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for …See details»

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding …

Mar 21, 2023 · To further enhance immune responses, the vaccine was adjuvanted with a novel toll-like receptor 3/RIG-I agonist (Riboxxim™), consisting of synthetic short double stranded RNA.See details»

RIBOXX PHARMACEUTICALS Announce an Exclusive License …

Feb 9, 2016 · Riboxx will be responsible for manufacturing and supply of APOXXIM® to TOLLYS. APOXXIM® is a Toll-like Receptor 3 (TLR3)-ligand that eliminates cancer cells by activating …See details»

riboxx RNA Technologies - Working at riboxx

Riboxx is a company with a strong focus on innovation and quality. Our corporate values define us as employees and workers at riboxx.See details»

Riboxxim - Drug Targets, Indications, Patents - Synapse - Patsnap

Riboxxim: a RIG-I modulators, TLR3 agonists Drug, Initially developed by Riboxx Pharmaceuticals, Now, its global highest R&D status is Preclinical, Mechanism: RIG-I …See details»

riboxx RNA Technologies - home

Home; products. IN VIVO siRNA. iVORi siRNA; IN VIVO miRNA mimics. CONmiR miRNA mimics; TLR3 ligands. RIBOXXOL; IN VIVO TLR3 ligands. RIBOXXOL CLINIgrade; RIG-I ligandsSee details»

Riboxx | VentureRadar

Riboxx GmbH is an international provider of innovative, customized and tailor-made molecular tools for gene silencing in vitro and in vivo through... ... Find out more about Riboxx, …See details»

linkstock.net © 2022. All rights reserved